episode 897: COVID-19 clinical update #113 with Dr. Daniel Griffin
In COVID-19 clinical update #113, Dr. Griffin discusses tocilizumab use in hospitalized Patients, IL-6 inhibitors and mortality, Baricitinib in hospitalized patients, post-infection neurological sequelae, comparative effectiveness of Pfizer and Moderna vaccines, phase 2/3 study of Paxlovid, infection relapse following Paxlovid, pre-hospital administration of Remdesivir, and hospitalization with different variants.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Timing of Tocilizumab Use in Hospitalized Patients (NIH)
- Interleukin-6 inhibitors reduce mortality (European Journal of Internal Medicine)
- Treatment Effect of Baricitinib on Hospitalized Patients (IDSA)
- Post Infection Neurological Sequelae (Res Square)
- Comparative Effectiveness of Pfizer and Moderna Vaccines (Nature Commun)
- Results from Phase 2/3 Study of Paxlovid (Pfizer)
- Infection Relapse Following Suppression by Paxlovid (Res Square)
- Update on Paxlovid Usage (FDA)
- Availability and Use of Treatments in Outpatients (CDC)
- Pre-Hospital Administration of Remdesivir (IDSA)
- Remdesivir and three other drugs for Hospitalized Patients (Lancet)
- Guidelines on Usage of Anticoagulants (Am Soc Hematol)
- Different Variants Hospitalization and Morality (Res Square)
- Contribute to FIMRIC fundraiser at PWB
- Dr. Griffin’s treatment guide (pdf)
- Letters read on TWiV 897
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to daniel@microbe.tv